Key result
Type 2 diabetes did not alter the heart rate and contractile response to β-adrenergic stimulation, though controls required a 36% higher dobutamine dose to reach 85% of maximal HR (P<0.05).
Why the study?
Does uncomplicated type 2 diabetes alter the chronotropic and inotropic response of the heart to β-adrenergic stimulation compared to matched controls?
Case-Control (n=15)
Does uncomplicated type 2 diabetes alter the chronotropic and inotropic response of the heart to β-adrenergic stimulation compared to matched controls?
In uncomplicated type 2 diabetes, the heart works at smaller volumes but maintains normal chronotropic and contractile responsiveness to β-adrenergic stimulation.
Supports preserved β-adrenergic responsiveness in uncomplicated T2D; hypothesis-generating for reduced exercise capacity mechanisms.
Type 2 diabetes (T2D) is associated with reduced cardiac reserve and aerobic capacity. Altered myocardial autonomic nervous regulation has been demonstrated in humans with diabetes (indirectly) and animal models (directly). PURPOSE: This study aimed to determine the chronotopic and inotropic response of the type 2 diabetic heart to β-adrenergic stimulation. METHODS: Eight people with uncomplicated T2D and seven matched controls performed a dual-energy x-ray absorptiometry scan and V˙O2peak test. Plasma catecholamines were determined at rest and during peak exercise. On a second visit, HR and left ventricular contractility were assessed using echocardiography during supine rest, parasympathetic blockade (atropine), and during incremental β-adrenergic stimulation (dobutamine). RESULTS: V˙O2peak and HR reserve were lower in T2D (P < 0.05) as expected. Both groups increased norepinephrine comparably (P = 0.23) during peak exercise; however, epinephrine increased less in the T2D group (P < 0.05). The dobutamine dose required to achieve 85% of age-predicted maximal HR was 36% higher in CON (P < 0.05). Resting HR was higher (P < 0.01) and stroke volume indexed to fat free mass was smaller (P < 0.05) in T2D. During dobutamine infusion the response (% change) in HR, end-diastolic volumeFFM, stroke volume, ejection fraction, and cardiac output were not different between the groups. However, HR was higher (P < 0.01) and end-diastolic volume indexed to fat free mass (P < 0.01), stroke volumeFFM (P < 0.01), ejection fraction (P < 0.05), and stroke work (P < 0.01) were lower in T2D. CONCLUSIONS: Although the type 2 diabetic heart worked at smaller volumes, the HR and contractile response to β-adrenergic stimulation were unaffected by diabetes. The reduced cardiac reserve observed in uncomplicated T2D was not explained by impaired myocardial sympathetic responsiveness but may reflect changes in the loading conditions or function of the diabetic left ventricle.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2016) conducted a case-control in Type 2 diabetes (n=15). Type 2 diabetes vs. Matched controls was evaluated on Chronotropic and inotropic response (% change in heart rate, end-diastolic volume, stroke volume, ejection fraction, and cardiac output) to β-adrenergic stimulation. Type 2 diabetes did not alter the heart rate and contractile response to β-adrenergic stimulation, though controls required a 36% higher dobutamine dose to reach 85% of maximal HR (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: